[EN] CURCUSONE DITERPENOIDS AND USES THEREOF<br/>[FR] DITERPÉNOÏDES DE CURCUSONE ET LEURS UTILISATIONS
申请人:PURDUE RESEARCH FOUNDATION
公开号:WO2022072266A1
公开(公告)日:2022-04-07
The present disclosure provides the first asymmetric total synthesis and target identification of the curcusone natural products. The novel convergent synthesis is built upon a cheap and abundant chiral pool molecule (8) and features a thermal [3,3]-sigmatropic rearrangement and an FeCl3-promoted global hydrolysis/adol condensation cascade to rapidly construct the critical cycloheptadienone core. By performing chemoproteomics with the alkyne probe 37, we identified the previously "undruggable" oncogenic protein BRAT1 as a key cellular target of 1d. Furthermore, 1d inhibits BRAT1 in cancer cells, thereby reducing cancer cell migration, increasing susceptibility to DNA damage, and inducing chemosensitization to the approved drug etoposide. Compound 1d is the first known small-molecule inhibitor for BRAT1, a master regulator of the DDR and DNA repair. Composition matters and methods of uses are within the scope of this disclosure.
本公开提供了curcusone天然产物的第一种不对称全合成和靶标鉴定。这种新颖的汇合合成是基于一种廉价和丰富的手性池分子(8)构建的,并具有热[3,3]-Sigmatropic重排和FeCl3促进的全局水解/Adol缩合级联反应,以快速构建关键的环庚二烯酮核心。通过使用炔基探针37进行化学蛋白质组学,我们确定了之前“无法治愈”的致癌蛋白BRAT1作为1d的关键细胞靶标。此外,1d在癌细胞中抑制BRAT1,从而减少癌细胞迁移,增加对DNA损伤的敏感性,并诱导对批准药物依托泊苷的化疗敏感性。化合物1d是BRAT1的第一种已知小分子抑制剂,是DDR和DNA修复的主要调节因子。本公开的范围包括组合物和使用方法。